Key Takeaways
- • SoundHealth closed an oversubscribed Series A financing round led by Shangbay Capital, raising $12.25 million and bringing total funding to date to that amount.
- • The company develops personalized, AI-enabled, non-invasive medical devices targeting FDA-cleared therapeutics for population-scale breathing and sleep disorders.
- • SoundHealth has achieved clinical adoption with endorsements from more than 1,000 healthcare professionals nationwide, indicating established market traction prior to Series A close.
- • Series A capital will be deployed to accelerate portfolio growth and expand commercialization of the company's sleep and breathing disorder treatment devices.
Summary
SoundHealth, a San Francisco-based medical technology company, announced the closing of an oversubscribed Series A financing round led by Shangbay Capital. The round brought the company's total funding to $12.25 million, marking a significant milestone in the company's development stage.
The company specializes in personalized, AI-enabled, non-invasive medical devices designed to address breathing and sleep disorders at population scale. SoundHealth's product portfolio consists of FDA-cleared therapeutics, indicating the company has achieved regulatory clearance for at least its initial offerings. This regulatory pathway completion prior to Series A demonstrates material de-risking of the underlying technology and clinical validation.
A key indicator of market validation is SoundHealth's professional adoption rate: the company reports recommendations from more than 1,000 healthcare professionals nationwide. This level of clinical endorsement suggests meaningful physician adoption and confidence in the company's therapeutic approach, providing a distribution foundation for commercialization efforts.
The capital raised in this Series A round will be directed toward accelerating growth across SoundHealth's device portfolio and expanding market penetration in sleep disorder and breathing treatment categories. The oversubscription of the round indicates strong investor demand and confidence in the company's market opportunity within the broader medical device and digital health sectors.
The company specializes in personalized, AI-enabled, non-invasive medical devices designed to address breathing and sleep disorders at population scale. SoundHealth's product portfolio consists of FDA-cleared therapeutics, indicating the company has achieved regulatory clearance for at least its initial offerings. This regulatory pathway completion prior to Series A demonstrates material de-risking of the underlying technology and clinical validation.
A key indicator of market validation is SoundHealth's professional adoption rate: the company reports recommendations from more than 1,000 healthcare professionals nationwide. This level of clinical endorsement suggests meaningful physician adoption and confidence in the company's therapeutic approach, providing a distribution foundation for commercialization efforts.
The capital raised in this Series A round will be directed toward accelerating growth across SoundHealth's device portfolio and expanding market penetration in sleep disorder and breathing treatment categories. The oversubscription of the round indicates strong investor demand and confidence in the company's market opportunity within the broader medical device and digital health sectors.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.